Bromantane 60x25mg

                                           NOT FOR HUMAN CONSUMPTION

Bromantane (trade name: Ladasten) is an atypical psychostimulant and adaptogen originally developed and used clinically in Russia. It is recognized for its unique blend of stimulant, anxiolytic, and adaptogenic properties. Unlike classical stimulants, Bromantane is believed to enhance physical and mental performance without significant adverse stimulation or dependence potential.

Chemical and Pharmacological Profile

• Chemical Name: N-(4-Bromophenyl)adamantan-2-amine

• Chemical Class: Adamantane derivative

• Classification: Actoprotector, Adaptogen, Psychostimulant

• Developer: Developed in Russia during the 1980s-1990s

• Trade Name: Ladasten

• Administration: Oral (capsules, powder form)

Mechanism of Action

Bromantane has a unique, multimodal pharmacological profile involving dopaminergic, serotonergic, and neuroprotective systems:

1. Dopaminergic Modulation

• Increases dopamine synthesis by upregulating tyrosine hydroxylase (TH) and aromatic L-amino acid decarboxylase (AAAD), key enzymes in dopamine production.

• Indirectly enhances dopamine release and activity in key brain regions involved in motivation, reward, and focus.

2. Serotonergic Modulation

• Mildly enhances serotonin production, contributing to mood improvement, reduced anxiety, and better stress resistance.

3. Adaptogenic and Anxiolytic Effects

• Demonstrates adaptogenic properties by improving stress resilience and normalizing neurochemical responses under stress.

• Exhibits anxiolytic (anti-anxiety) effects without typical sedation, believed to be related to modulating serotonin, dopamine, and possibly GABAergic neurotransmission.

4. Neuroprotective and Antioxidant Properties

• Possesses antioxidant potential, reducing oxidative stress in neuronal tissues.

• Enhances neurotrophic factors, potentially promoting neurogenesis and cognitive enhancement.

5. Physical Performance Enhancement

• Classified as an "actoprotector," meaning it can boost physical performance and endurance, while reducing fatigue.

Potential Therapeutic and Experimental Applications

Initially developed in Russia, Bromantane (Ladasten) is primarily used for its adaptogenic, anti-fatigue, cognitive-enhancing, and anxiolytic properties:

1. Cognitive and Psychological Benefits

• Enhances cognitive performance, attention, focus, motivation, and mental stamina.

• May improve memory consolidation and retrieval through increased neuroplasticity.

• Potential application in addressing cognitive fatigue, attention deficits, and depressive mood disorders.

2. Anti-Fatigue and Performance Enhancement

• Improves physical performance, reduces perceived exertion, and increases energy levels.

• Potentially beneficial in competitive sports (note: banned by WADA) or physically demanding occupations.

3. Anxiety and Stress Resistance

• May decrease anxiety symptoms and enhance overall emotional resilience under stress, making it potentially useful in stress-related disorders.

4. Mood Regulation

• Anecdotal reports and limited clinical studies suggest Bromantane could alleviate symptoms of mild-to-moderate depression through its dopaminergic and serotonergic modulation.

Dosage and Administration Guidelines (Experimental Context)

Typical dosage ranges (based on available clinical literature and anecdotal reports):

• Low Dose: 25–50 mg/day (mild cognition-enhancing, anxiolytic effects)

• Moderate Dose: 50–100 mg/day (more pronounced adaptogenic, mood-elevating, and performance benefits)

• High Dose: Up to 100–200 mg/day (occasionally used experimentally, but higher dosages may increase risk of side effects)

Administration Considerations

• Usually taken orally once daily, preferably in the morning due to potential stimulating effects.

• Bromantane has a relatively long half-life (~11–15 hours), making once-daily dosing practical.

• Cycle duration typically ranges from 1–4 weeks, followed by breaks to prevent tolerance development, although tolerance appears minimal compared to classical stimulants.

Safety Profile and Potential Side Effects

Bromantane generally shows a favorable safety profile with relatively mild adverse effects compared to traditional stimulants:

Commonly Reported Side Effects (Usually Mild):

• Mild stimulation or restlessness at higher doses

• Insomnia or sleep disturbances, especially if dosed late

• Mild headaches or dizziness

• Nausea or mild gastrointestinal discomfort

Rare or High-dose Side Effects:

• Anxiety or agitation at excessive dosages

• Increased blood pressure or heart rate at high doses

• Possible interactions with other stimulants or serotonin-modulating medications

Dependence and Withdrawal Potential

• Limited reports suggest low risk of tolerance, dependence, or addiction with responsible use.

• However, regular monitoring and periodic cycling are recommended to maintain efficacy and safety.

Contraindications and Drug Interactions

Contraindications:

• Severe cardiovascular conditions or uncontrolled hypertension

• Pregnancy and breastfeeding (due to lack of safety data)

• History of severe psychiatric disorders, unless medically supervised

Drug Interactions:

• Potential interaction with stimulant medications (amphetamines, modafinil, methylphenidate) increasing cardiovascular and CNS stimulation risks.

• Theoretical risk of serotonin syndrome when combined with serotonergic drugs (SSRIs, MAOIs, tricyclic antidepressants); thus, caution and medical supervision recommended.

Legal and Regulatory Status

• Russia: Approved as Ladasten for clinical use; available by prescription for neurasthenia, fatigue syndromes, anxiety, and depression.

• Internationally (US, EU, Canada, Australia): Not approved or regulated by FDA, EMA, or analogous agencies. Sold primarily as a research chemical or dietary supplement, often with limited legal oversight.

• World Anti-Doping Agency (WADA): Bromantane is classified as a prohibited stimulant; banned in competitive sports.

Current Research and Clinical Evidence

Bromantane's existing research is primarily documented in Russian-language studies and limited international publications. Key findings include:

• Clinical studies indicate improvements in cognitive performance, mood, fatigue reduction, and emotional resilience.

• Animal studies suggest neuroprotective, adaptogenic, and performance-enhancing properties, with potential antidepressant and anxiolytic effects.

• Limitations: Insufficient large-scale randomized controlled trials (RCTs) exist in Western scientific literature. More robust clinical research is necessary to conclusively establish therapeutic efficacy and long-term safety.

Summary of Potential Benefits and Risks

 References 

• Morozov IS, Ivanova IA, Lukicheva TA. Actoprotector and adaptogen Ladasten. Eksp Klin Farmakol. 2001;64(1):57-60.

• Neznamov GG, Teleshova ES. Comparative studies of Ladasten and other actoprotectors in patients with asthenic disorders. Neurosci Behav Physiol. 2009;39(6):545-551.

• Tiurenkov IN, Bagmetova VV, Epishina VV, et al. Neurochemical mechanisms underlying the pharmacological effects of Ladasten. Bull Exp Biol Med. 2012;153(6):720-72